骨膜软骨性肿瘤良恶性鉴别的影像特征
回顾性分析两所肉瘤中心89例经病理证实的骨膜软骨瘤与骨膜软骨肉瘤,纳入至少有一种X线、CT或MRI检查的病例。结果显示肿瘤长径≥5cm、体积≥19cm³、特定部位、侵袭性骨膜反应及瘤周软组织水肿与恶性相关。
要点
- 长径≥5cm是恶性最强独立预测因素,阅片时应优先测量并记录。
- 扁平骨和肱骨部位骨膜软骨性肿瘤应提高恶性警惕。
- 出现侵袭性骨膜反应和瘤周软组织水肿时,联合特征可提升诊断信心。
核心结论
- 影像学可较可靠地区分骨膜软骨瘤与骨膜软骨肉瘤,形状影像组学在简单肿瘤大小评估基础上无明显增量价值。
研究设计与样本
- 回顾性研究,纳入2001–2024年两所肉瘤参考中心经病理证实的89例骨膜软骨瘤和骨膜软骨肉瘤患者。
- 纳入标准为至少有一种影像检查(X线、CT或MRI),中位年龄31岁,骨膜软骨肉瘤占32.6%。
关键影像表现/征象
- 恶性相关影像征象包括长径≥5cm、体积≥19cm³、扁平骨和肱骨部位、侵袭性骨膜反应、Lodwick分级、瘤周软组织水肿和对比增强。
- 形状影像组学中肿瘤体积AUROC最高(0.923),但未优于长径(AUROC=0.903,DeLong P=0.65)。
诊断标准与关键数值
- 长径≥5cm:OR=76.29,P<0.0001。
- 部位:肱骨OR=21.68,P=0.0239;扁平骨OR=32.63,P=0.0475。
- 恶性相关变量:长径≥5cm(P<0.0001)、体积≥19cm³(P<0.0001)、扁平骨和肱骨部位(P<0.0001)、侵袭性骨膜反应(P=0.0002)、Lodwick分级(P=0.0004)、瘤周软组织水肿(P=0.0128)、对比增强(P=0.0306)。
- 多因素分析识别四个恶性相关变量:肿瘤大小、部位、瘤周软组织水肿和侵袭性骨膜反应。
临床应用与阅片要点
- 阅片时应常规测量肿瘤最长径,长径≥5cm需高度怀疑骨膜软骨肉瘤。
- 位于扁平骨或肱骨的骨膜软骨性肿瘤应提高恶性警惕。
- 报告应描述骨膜反应类型及瘤周软组织水肿有无,作为良恶性辅助鉴别依据。
- 联合大小、部位、骨膜反应和瘤周水肿至少两个特征时,可较准确提示恶性。
局限性
- 回顾性设计,仅纳入两所肉瘤参考中心病例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: Periosteal cartilaginous tumors, comprising periosteal chondroma (PCh) and periosteal chondrosarcoma (PChS), are uncommon bone surface tumors that remain poorly characterized radiologically. This study aimed to identify clinical, and imaging features distinguishing PChS from PCh.
METHODS: A retrospective analysis was conducted on patients with histologically-confirmed PCh and PChS from two sarcoma reference centers (2001-2024). Inclusion required at least one imaging modality (X-ray, CT or MRI). Radiological features depicting the tumor dimensions, matrix, and peritumoral changes (including periosteal reaction, peritumoral edema and enhancement patterns) were collected. Tumor shape was quantified using shape radiomics. Uni- and multivariable analyses (including area under the ROC [AUROC] analysis, Student, Wilcoxon, Chi-square tests, and stepwise binary logistic regression) were used to identify predictors of PChS.
RESULTS: 89 patients were included (median age: 31 years, 32.6% PChS). Several variables were associated with PChS: longest diameter (LD) ≥5cm (P < 0.0001), volume ≥19cm3 (P < 0.0001), flat bone and humerus locations (P < 0.0001), aggressive periosteal reaction (P = 0.0002), Lodwick classification (P = 0.0004), peritumoral soft-tissue edema (P = 0.0128) and contrast-enhancement (P = 0.0306). Among shape radiomics features, tumor volume achieved the highest AUROC (0.923) but did not outperform LD (AUROC=0.903, DeLong P = 0.65). Stepwise multivariable analysis identified four variables associated with malignancy: tumor size, location, peritumoral soft-tissue edema, and aggressive periosteal reaction. Among these, LD ≥ 5 cm (OR = 76.29, P < 0.0001) and location (humerus: OR = 21.68, P = 0.0239; flat bones: OR = 32.63, P = 0.0475) were independent predictors. Diagnostic performance was highest when at least two of these four features were present (accuracy=93.1%), with perfect specificity when three were present.
CONCLUSIONS: Imaging can reliably distinguish benign from malignant periosteal cartilaginous tumors, whereas shape radiomics provides no meaningful incremental value over simple tumor size assessment.
ADVANCES IN KNOWLEDGE: Integrating clinical, CT, and MRI features provides high diagnostic accuracy in distinguishing benign from malignant periosteal cartilaginous tumors.
引用
- Parmeggiani, Crombé, Fadli, et al. Imaging features reliably distinguish malignancy in periosteal cartilaginous tumors: a two-center analysis of 89 patients. Br J Radiol. 2026. PMID: 42773506. doi:10.1093/bjr/tqag230
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。